Biomea Fusion
BMEA----
Biomea Fusion (BMEA)
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diab...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Biomea Fusion Analyst Rating
View MoreForecast & Rating
Jun 23, 2026Price forecast
$6.83440.18%
Forecast & RatingBuy
7analysts
- Strong buy57.14%
- Buy28.57%
- Hold0.00%
- Sell0.00%
- Strong sell14.29%
News
- Global Report · 1 day ago, 04:17 AM
Niche Market Moves: Major Overhauls From Energy to AI Infrastructure
- Global Report · Jul 9 at 05:03 AM
Unbundling the Long Tail: Narrative Arbitrage and Value Chain Realities
- Global Report · Jul 8 at 10:32 PM
Markets Weigh Cross-Sector Fundamentals for Signals on the Next Economic Phase
- nasdaq · Jun 8 at 07:10 AM
Biomea Presents Promising Phase 2 Data For Icovamenib In Diabetes; Advances Phase 1 For BMF-650
- StockTitan · Jun 5 at 10:35 AM
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study | BMEA Stock News
- Earnings Watch · May 11 at 04:05 PM
Biomea Fusion | 10-Q: FY2026 Q1 Revenue: USD 0
